PHGE stock forecast
Our latest prediction for BiomX Inc's stock price was made on the July 28, 2021 when the stock price was at 4.67$.
In the short term (2weeks), PHGE's stock price should outperform the market by 2.29%. During that period the price should oscillate between -10.01% and +17.27%.
In the medium term (3months), PHGE's stock price should underperform the market by -1.18%. During that period the price should oscillate between -38.64% and +38.88%.
Get email alertsCreate a solid portfolio with PHGE
About BiomX Inc
biomx is a microbiome drug discovery company developing customized phage therapies that target and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (ibd) and cancer. we discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. the company’s platforms use computational and synthetic biology and cutting-edge research from profs. rotem sorek, ph.d., eran elinav, m.d., ph.d., and eran segal, ph.d., of the weizmann institute of science; and professor timothy k. lu, m.d., ph.d., of the massachusetts institute of technology. investors in the company include orbimed israel incubator lp, johnson & johnson development corporation inc., takeda ventures, inc., seventure partners, mirae asset global investments, and sbi.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.30$ per share.
The book value per share is 0.22$
Three months stock forecastJuly 28, 2021
Financials
Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|---|---|---|
- | - | -33M | - | -33M | -1.30 | - | - | 23M | 0.22 | -24M | -2M | -26M |